Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company specializing in biomarkers and augmented intelligence for chronic low back pain diagnosis, announced the appointment of Daniel Keefe as Commercial Director, Western U.S. Keefe will lead commercial expansion across the Western region, building on Aclarion's existing footprint and supporting continued adoption of Nociscan, the company's cloud-based platform that helps physicians identify painful discs noninvasively.
Keefe brings over 20 years of medical device and healthcare technology sales experience, including leadership roles at Centinel Spine, Brainlab, Zimmer Biomet, and Intuitive Surgical. Most recently, he served as Regional Sales Manager at Centinel Spine, where he consistently exceeded performance targets and delivered significant year-over-year growth across Northern California. His expertise spans capital equipment, surgical technologies, and advanced clinical solutions across spine, orthopedics, and image-guided surgery.
"Dan brings a proven track record of driving commercial growth and expanding adoption of innovative surgical technologies. His deep experience working with spine surgeons and hospital systems, combined with his ability to build and scale high-performing territories, will be instrumental as we continue to grow our presence in the Western U.S. and support broader clinical use of Nociscan," said Brent Ness, Chief Executive Officer of Aclarion.
The appointment reflects growing demand for Nociscan, which has seen triple-digit growth in utilization. Aclarion has established a presence across the Western U.S., with engagement spanning academic institutions and high-volume private practice spine centers. Keefe's role is part of the company's strategy to expand this momentum and deepen adoption in a key strategic region.
"I'm excited to join Aclarion at a time when Nociscan is gaining meaningful traction across the clinical community. The ability to provide physicians with objective insight into the source of pain represents a significant advancement in how chronic low back pain is evaluated. I look forward to working with physicians and spine centers across the Western U.S. to expand access to Nociscan and support its continued integration into clinical practice," said Daniel Keefe.
An estimated 266 million people worldwide live with chronic low back pain. Aclarion's Nociscan is the first evidence-supported, cloud-based platform to noninvasively help physicians distinguish between painful and nonpainful discs. It quantifies chemical biomarkers associated with disc pain and, when used with other diagnostic tools, demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated. For more information on Nociscan, visit Aclarion's website. To find a Nociscan center, view the site map.
